

LAVILON

Lotion Antichute

Double Blind Clinical Trial for the evaluation of efficacy, skin tolerance and cosmetic acceptability of LAVILON LOTION ANTICHUTE compared with a similar reference product.

100 subjects with androgenetic alopecia


(two groups of 70 males and 30 females; Age 30 - 50 years old).

Treatment duration: 3 months in comparison with a similar reference product


LAVILON

Lotion Antichute

Clinical Improvement of Hair Loss



Control (Anagen 3)




LAVILON

Lotion Antichute

Promotion of hair in anagen phase

Anagen/Non Anagen Ratio



■ LAVILON LOTION ANTICHUTE
■ CONTROL (ANAGEN 3)

70%

Promotion of healthy hair
in anagen phase

Trichogram

Increased diameter of shaft

	Mean shaft diameter (mm)	
LOTION ANTICHUTE	0.040	0.095 p<0.05
Control (Anagen 3)	0.040	0.065 p=n.s.

138%

Increase in hair density

Greater cosmetic acceptability

Excellent tolerability